The results of the SLR informed this ITC; it was expected that according to the international guidelines, C1-INH(IV) and C1-INH(SC) would be the comparators to lanadelumab in pediatric patients with HAE, as these are the only LTP options recommended in patients aged <12 years. The gene discussed is SERPING1; the disease is hereditary angioedema.